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specimens with SFC with sensitlwty 83% and specificity 86%. 
Conclusion IF at&=480 nm identifies SFC in plaques with high content of PG and SMC 
and in thin fibrous cap atheromas. 
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820-l A Prospective, Randomized Trial of 
Thromboatherectomy During Intervention of 
Thrombotic Native Coronary Arteries and Saphenous 
Vein Grafts: The X-TRACT Trial 
Grsqa W. Stone, David A. Cox, Joseph D. Babb, Dean Nukta, Luc Bilodeau, Louis 
Cannon, Thomas D. Stuckey, James Hermiller, Eric Cohen, Reginald Low, Alexandra J. 
Lansky, Steven R. Bailey, Richard E. Kuntz, Cardiovascular Research FoundationlLenox 
Hill Heart and Vascular Institute, New York, NY 
Background. Peri-procedural complications are increased during PCI of SVGs and 
native coronary arleries containing thrombus. Whether outcomes may be improved by 
thrombectomy prior to intervention is unknown. 
Methods. At 75 U.S. sites, 800 consecutive pts with diseased SVGs (72%) or native cor- 
onary lesions containing thrombus (28%) were prospectively randomized to standard 
PCI vs. thromboatherectomy with the ev3 X-SIZER followed by PCI. Randomization was 
stratified by Ilb/llla use. 
Results. Baseline clinical and angiographic characteristics were well matched, excepi 
that by core lab determination X-SIZER patients were more likely to have thrombus 
present (70% vs. 58%, p<O.OOl), and had a slightly greater initial diameter stenosis (70% 
vs. 67%, p-zO.05). GP Ilb/llla inhibitors were administered in 78% of each group. Rates of 
post procedure TIMI flow, no reflow and distal emboli were similar in the 2 groups. 
Among pts not receiving upfront Ilb/lila inhibitors, ball-out Ilb/llla use was required in 
fewer patients treated with the X-SIZER (2.1% vs. 10.3%, p=O.O2). The 30.day compos- 
ite major adverse cardiac event rate (death, MI, or TVR) was similar in pts treated with X- 
SIZER vs. control (17.0% vs. 17.4% respectively, p=NS). The X-SIZER did, however, 
lower the pre-specified rate of large Ml (Q-wave Ml or peak CPK-MB >8x nl) by 41% 
(5.5% vs. 9.6%, p=O.O3). After accounting for the difference in baseline thrombus and 
lesion severity by multwariate analysis, use of the X-SIZER was an independent predlc- 
tor of freedom from large Ml (odds ratio = 0.35, p=O.O02) and death or large Ml (OR = 
0.43, p&006). 
Conclusions. Performance of thromboatherectomy with the X-SIZER prior to PCI in dis- 
eased SVGs or thrombotlc native coronary lesions does not reduce the overall 30 day 
composite rate of adverse events. X-SIZER use does, however, reduce procedural com- 
plications as evidenced by less need for bail-out GP Ilb/llla inhibitors, and enhances 30. 
day survival free from large MI. 
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820-2 Treatment of Saphenous Vein Bypass Grafts With 
Ultrasound Thrombolysis: A Randomized Study 
Mandeeo Sinoh Uri Rosenscheim. Kalon K. Ho, Peter B. Berger, Richard Kuntz, David 
R. Holmes, Jr., Mayo Clinic, Rochester, MN 
BackgroundPercutaneous coronary interventions (PCI) I” patients with saphenous vein 
grafts (SVG) have a high frequency of distal embolization and other adverse clinical 
events, particularly if thrombus is present. Acolysis (therapeutic ultrasound) has the abil- 
ity to break up thrombus in vitro, in animal models, and in humans. Whether this is bene- 
ficial during percutaneous SVG interventions is unknown. 
ObjectiveWe performed a randomized trial of Coronary Ultrasound Thrombolysis (CUT) 
in which patients with an acute coronary syndrome undergoing PCI in a SVG were ran- 
domly assigned to receive treatment with acolysis or therapy with abciximab. The pri- 
mary end point of study was a successful procedure without complications at 30 days 
defined as a final luminal diameter stenosis <30% by quantitative angiographic analysis 
with Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow and freedom from major 
adverse cardiac events (MACE- a composite of death, Q and non-Q-wave myocardial 
infarction, emergency bypass surgery, disabling stroke, and target lesion revasculariza- 
tron) at 30 days. 
Results. One hundred and eighty one patients, 92 randomized to acolysis and 89 to 
abciximab, were enrolled. The two groups were well matched for baseline and lesion 
characteristics. Angiographic procedural success was achieved in 83% of patients ran- 
domized to acolysis and 82% randomized to abciximab (p=O.O08). The cumulative inci- 
dence of MACE at 30 days was 25% I” the acolysis vs. 12% in the abciximab group 
(p=O.O38). due mainly to a greater frequency of non-Q-wave myocardial infarction 
(19.6% vs 7.9%, p=O.O3) in patients treated with acolysis. The incidence of Q-wave myo- 
cardial InfarctIon was also higher in patients treated with acolysis (5.4% vs 2.2%, p=NS). 
The primary end point was thus achieved in 53.8% of acolysis and 73.1% of abciximab 
patients (p=O.O14) 
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ConclusionsIn this randomized trial, use of therapeutic ultrasound in vein graft lesions 
in patients with acute coronary syndrome was associated with poor angiographic out- 
come and increased the incidence of acute ischemic complications. 
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820-3 Predictors of Adverse Clinical Outcome in the 
Randomized Evaluation of Covered Stent in Saphenous 
Vein Graft (RECOVERS) Trial 
Goran Stank@& Antonio Colombo, Fabio Sgura, Flavio Airoldi, Carlo Briguori, 
Nicholaous Reifart, Patrizia Presbitero, Luigi Inglese. G. Heyndrickx, Carlo Di Mario, 
EM0 Centro Cuore Columbus, Milan, Italy. San Raffaele Hospital, Milan, Italy 
In the Randomized Evaluation of Covered Stent in Saphenous Vein Graft (RECOVERS) 
trial polytetrafluoroethylene (PTFE) covered stent was compared with stainless steel 
(SS) stent for prevention of major adverse cardiac events (MACE) for treatment of 
saphenous vein graft (SVG) lesions. The results of this trial have already been pre- 
sented. We aimed to determine clinical, angiographic and procedural predictors of 
adverse B-month clinical outcome. 
Methods and results: 292 pts ware randomized to PTFE JOSTENT (152 pts) and SS 
JOSTENT Flex (140 pts). Pts received aspirin and ticlopidine for 3 months. MACE were 
defined as death, myocardial infarction (Ml) and repeat revascularization. Cumulative 8- 
month MACE rate was 31% in PTFE group vs 19% in SS group (P=O.Ol), with Ml rate of 
14% vs 5.5% (P=O.O2). 
Multivariate analysis identified following predictors of Ml: prior stroke (coeff -2.46, 
P=O.O06), ref. vessel size (c&f. -1.52, P=O.O03), stent length (coeff. -0.11. P=O.O2), final 
min. lumen diameter (coeff 1.21, P=O.O3). Predictors of cumulative MACE were: use of 
PTFE stents (co& 0.78, P=O.O2), lesion length (coeff -0.05, PcO.02) and trend was 
found for COmDlianCs to 3-month ticlooidine theraov fceof 0.76. P=O.O9). Fioura shows 
. L .  I” 
calculated probability of MACE according to lesion length, compliance to 3 month ticlopi- 
dine therapy and use of PTFE stents. Conclusion: Use of PTFE covered stents to treat 
long SVG lesions and non-compliance to ticlopidine therapy negatively affects six-month 
clinical outcome 
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A Prospective Randomized Multicenter Trial Comparing 
Distal Protection During Saphenous Vein Graft 
Intervention With a Filter-Based Device Compared to 
Balloon Occlusion and Aspiration: The FIRE Trial 
Greoa W. Stone, Campbell Rogers, James Hermiller, Robert Feldman, Patrick Hall, 
Robert Haber, A. Masud, Patrick Cambier, Ronald P. Caputo, Mark Turco, Richard 
Kovach, Bruce R. Brodie. Howard Herrmann. Richard Kuntz, Steve Ramee, David A. 
Cox, Cardiovascular Research FoundationlLenox Hill Heart and Vascular Institute, New 
York, NY 
Background. Percutaneous intervention (PCI) in diseased saphenous vain grafts (SVG) 
is associated with a high peri-procedural rate of complications. Distal protection dunng 
SVG PCI using a balloon occlusion and aspiration system (the PercuSurge GuardWire) 
has been shown in a large randomized trial to reduce 30 day MACE rates by 42%. Com- 
pared to balloon occlusion systems, filter-based distal protection devices may be simpler 
to use, and allow antegrade perfusion during the procedure, reducing ischemia time and 
facilitating intervention in pts with poor LV function. The absolute clinical efficacy of distal 
filters as an adjunct to PCI rn diseased SVGs has not been proven. however, nor has 
their relative efficacy compared to balloon occlusion/aspiration systems. 
Methods. We therefore performed a large, multicenter non-inferiority trial of PCI in dis- 
eased SVGs in which 650 consecutive pts at 65 U.S. and Canadian centers were ran- 
domized I:1 to intervention with distal protection using the BSC/EPI FillerWire EX vs. the 
PercuSurge GuardWire. The FilterWire consists of a microporous polyurethane net 
attached to a self-expanding nitinol ring anchored distally to a 0.014’ guidewire over 
which PCI is performed. Crossing profile is 3.9F. Randomization was stratified by use of 
Ilb/llla inhibitors, the administration of which was left to the discretion of the operators. 
The primary endpoint was the composite rate of death, Ml (CPK-MB z-3.x nl), CABG or 
target lesion revascularrzation at 30 days. 
Results. The last patient was enrolled in August, 2002. Pooling the pts, the mean age 
was 69+ 10 years, 21% were female, 31% had prior MI. 39% had diabetes, 82% hyper- 
tension, 86% hyperlipidemia, and 12% renal insufficiency. Baseline LVEF was 49% -+ 
12%. The mean graft age was 11 _+8 years. 
Conclusions. FIRE is the first completed large-scale randomized trial comparing filter- 
